Myricx Bio Announces Board Changes

London, UK, 09 July 2024 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), today announced the following board changes.

Dr Rachael Brake has stepped down as an independent Non-Executive Director.

Co-founder Professor Ed Tate has stepped down as Director but remains a Board Observer and closely involved with the company as a N-Myristoyltransferase (NMT) key opinion leader and Scientific Advisor to the company.

Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth have joined the Myricx’ Board as Investor Directors. Other board directors are Chris Martin, Independent Chair, Robin Carr, CEO, and Maina Bhaman from Sofinnova and Jonathan Tobin from Brandon Capital as Investor Directors.

Chris Martin, Chairman and Non-Executive Director of Myricx Bio said, “On behalf of the board I would like to take this opportunity to acknowledge and thank Rachael for everything she has done to help Myricx reach this point in the company’s evolution over the past two years. Rachael brought her +20 years’ experience in advancing therapeutic programs across various mechanisms of action and modalities in oncology and her deep experience of drug development to Myricx. Both in and outside board meetings Rachael has worked energetically to enable the company to sharpen its science strategy, and to understand how to effectively validate and position its novel NMT inhibitor platform.”

Myricx recently announced the closing of its series A financing raising £90m ($114m).

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-Myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets that are key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Abingworth, Brandon Capital Partners, British Patient Capital Cancer Research Horizons, Eli Lilly and Company, Novo Holdings, Sofinnova Partners.

For further information please contact

At the Company
Dr Robin Carr, CEO, Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 72658